Priority covid-19 vaccination for patients with cancer while vaccine supply is limited

Antoni Ribas, Rajarshi Sengupta, Trevan Locke, Sayyed Kaleem Zaidi, Katie M. Campbell, John M. Carethers, Elizabeth M. Jaffee, E. John Wherry, Jean Charles Soria, Gypsyamber D’souza

Research output: Contribution to journalArticlepeer-review

Abstract

Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

Original languageEnglish (US)
Pages (from-to)233-236
Number of pages4
JournalCancer discovery
Volume11
Issue number2
DOIs
StatePublished - Feb 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Priority covid-19 vaccination for patients with cancer while vaccine supply is limited'. Together they form a unique fingerprint.

Cite this